Ainsworth, T. M., Lynam, E. B., and Sklar, L. A. (1996). Neutrophil function in inflammation and infection. In ''Cellular and Molecular Pathogenesis'' (A. E. Sirica, Ed.), pp. 37—55. Lippincott-Raven, Philadelphia.

Akinshola, B. E., Chakrabarti, A., and Onaivi, E. S. (1999a). In-vitro and in-vivo action of cannabinoids. Neurochem. Res. 24(10), 233—240.

Akinshola, B. E., Taylor, R. E., Ogunseitan, A. B., and Onaivi, E. S. (1999b). Anandamide inhibition of recombinant AMPA receptor subunits in Xenopus oocytes is increased by forskolin and 8-bromo-cyclic AMP. Naunyn-Schmiedebergs Arch. Pharmacol. 360(3), 242-248.

Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K., and Walter, P. (2002). ''Molecular Biology of the Cell'' 4th edn. Garland Science, Taylor & Francis Group, New York, pp. 908, 931, 973-975.

Ali, H., Tomhave, E. D., Richardson, R. M., Haribabu, B., and Snyderman, R. (1996). Thrombin primes responsiveness of selective chemoattractant receptors at a site distal to G protein activation. J. Biol. Chem. 271(6), 3200-3206.

Antony, V. B., Sahn, S. A., Antony, A. C., and Repine, J. E. (1985). Bacillus Calmette-Guerin-stimulated neutrophils release chemotaxis for monocytes in rabbit pleural spaces and in vitro. J. Clin. Invest. 76(4), 1514-1521.

Arai, H., Tsou, C.-L., and Charo, I. F. (1997). Chemotaxis in a lymphocyte cell line transfected with C-C chemokine receptor 2B: Evidence that directed migration is mediated by betagamma dimers released by activation of G(alphai)-coupled receptors. Proc. Nat. Acad. Sci. USA 94(26), 14495-14499.

Armstrong, R. A. (1995). Investigation of the inhibitory effects of PGE2 and selective EP agonists on chemotaxis of human neutrophils. Br. J. Pharmacol. 116(7), 2903-2908.

Baker, D., Pryce, G., Davies, W. L., and Hiley, R. (2006). In silico patent searching reveals a new cannabinoid receptor. Trends Pharamacol. Sci. 27, 1-4.

Barann, M., Molderings, G., Bruss, M., Bonisch, H., Urban, B. W., and Gothert, M. (2002). Direct inhibition by cannabinoids of human 5-HT3A receptors: Probable involvement of an allosteric modulatory site. Br. J. Pharmacol. 137(5), 589-596.

Begg, M., Pacher, P., Batkai, S., Osei-Hyiaman, D., Offertaler, L., Fong, M. M., Liu, J., and Kunos, G. (2005). Evidence for novel cannabinoid receptors. Pharmacol. Ther. 106(2), 133-145.

Bennett, G., al-Rashed, S., Hoult, J. R. S., and Brain, S. D. (1998). Nerve growth factor induced hyperalgesia in the rat hind paw is dependent on circulating neutrophils. Pain 77(3), 315-322.

Bisogno, T., Hanus, L., De Petrocellis, L., Tchilibon, S., Ponde, D. E., Brandi, I., Moriello, A. S., Davis, J. B., Mechoulam, R., and Di Marzo, V. (2001). Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol. 134(4), 845-852.

Bokoch, G. M. (2005). Regulation of innate immunity by Rho GTPases. Trends Cell Biol. 15, 163-171.

Bouaboula, M., Rinaldi, M., Carayon, P., Carillon, C., Delpech, B., Shire, D., Le Fur, G., and Casellas, P. (1993). Cannabinoid-receptor expression in human leukocytes. Eur. J. Biochem. 214(1), 173-180.

Bouaboula, M., Dussossoy, D., and Casellas, P. (1999). Regulation of peripheral cannabinoid receptor CB2 phosphorylation by the inverse agonist SR144528. Implications for receptor biological responses. J. Biol. Chem. 274, 20397-20405.

Breivogel, C. S., Sim, L. J., and Childers, S. R. (1997). Regional differences in cannabinoid receptor/G-protein coupling in rat brain. J. Pharmacol. Exp. Ther. 282(3), 1632-1642.

Brown, A. J., and Wise, A. (2001). Glaxosmithkline, Identification of modulators of GPR55 activity. International Patent #: W00186305.

Brown, A. J., Ueno, S., Suen, K., Dowell, S. J., and Wise, A. (2005). /n Molecular idenfication of GPR55 as a third G protein-coupled receptor responsive to cannabinoid ligands Symp. Cannabinoids, /nt. Cannabinoid Res. Soc., Burlington, Vermont, Abstract, p. 16.

Buhl, A. M., Johnson, N. L., Dhanasekaran, N., and Johnson, G. L. (1995). Galpha12 and Galpha13 stimulate Rho-dependent stress fiber formation and focal adhesion assembly. J. Biol. Chem. 270(42), 24631-24634.

Bukoski, R. D., Batkai, S., Jarai, Z., Wang, Y., Offertaler, L., Jackson, W. F., and Kunos, G. (2002). CB1 receptor antagonist SR141716A inhibits Ca2+-induced relaxation in CB1 receptor-deficient mice. Hypertension 39(2), 251-257.

Campbell, J. J., Foxman, E. F., and Butcher, E. C. (1997). Chemoattractant receptor cross talk as a regulatory mechanism in leukocyte adhesion and migration. Eur. J. Immunol.

Christopoulos, A., and Kenakin, T. (2002). G protein-coupled receptor allosterism and complexing. Pharmacol. Rev. 54(2), 323-374.

Christopoulos, A., and Wilson, K. (2001). Interaction of anandamide with the M1 and M4 muscarinic acetylcholine receptors. Brain Res. 915(1), 70-78.

Cross, A., Bakstad, D., Allen, J. C., Thomas, L., Moots, R. J., and Edwards, S. W. (2005). Neutrophil gene expression in rheumatoid arthritis. Pathophysiology 12(3), 191-202.

De la Fuente, M., Carrasco, M., Del Rio, M., and Hernanz, A. (1998). Modulation of murine lymphocyte functions by sulfated cholecystokinin octapeptide. Neuropeptides 32(3), 225-233.

Derocq, J.-M., Jbilo, O., Bouaboula, M., Segui, M., Clere, C., and Casellas, P. (2000). Genomic and functional changes induced by the activation ofthe peripheral cannabinoid receptor CB2 in the promyelocytic cells HL-60. Possible involvement of the CB2 receptor in cell differentiation. J. Biol. Chem. 275(21), 15621-15628.

Deusch, E., Kraft, B., Nahlik, G., Weigl, L., Hohenegger, M., and Kress, H. G. (2003). No evidence for direct modulatory effects of Delta9-tetrahydrocannabinol on human polymorphonuclear leukocytes. J. Neuroimmunol. 141(1-2), 99-103.

Devane, W. A. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 252, 1946-1949.

Didsbury, J. R., Uhing, R. J., Tomhave, E., Gerard, C., Gerard, N., and Snyderman, R. (1991). Receptor class desensitization of leukocyte chemoattractant receptors. Proc. Natl. Acad. Sci. USA 88(24), 11564-11568.

Di Marzo, V., Bisogono, T., and De Petrocellis, L. (2000). Endocannabinoids: New targets for drug development. Curr. Pharm. Des. 6, 1361-1380.

Dong, X., Mo, Z., Bokoch, G., Guo, C., Li, Z., and Wu, D. (2005). P-Rex1 is a primary Rac2 guanine nucleotide exchange factor in mouse neutrophils. Curr. Biol. 15, 1874-1879.

Drmota, T., et al. (2004). AstraZenica, ''Screening assays for cannabinoid-ligand type modulators of GPR55. International Patent #: WO2004074844.

Ellerbroek, S. M., Wennerberg, K., and Burridge, K. (2003). Serine phosphorylation negatively regulates RhoA in vivo. J. Biol. Chem. 278(21), 19023-19031.

Entschladen, F., Drell, T. L. IV, Palm, D., Bastian, P., Potthoff, S., Zanker, K. S., and Lang, K. (2005). A comparative review on leukocyte and tumor cell migration with regard to the regulation by serpentine receptor ligands. Signal Transduct. 5(1-2), 9-18.

Fezza, F., Bisogno, T., Minassi, A., Appendino, G., Mechoulam, R., and Di Marzo, V. (2002). Noladin ether, a putative novel endocannabinoid: Inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Lett. 513(2-3), 294-298.

Franklin, A., and Stella, N. (2003). Arachidonylcyclopropylamide increases microglial cell migration through cannabinoid CB2 and abnormal-cannabidiol-sensitive receptors. Eur. J. Pharmacol. 474(2-3), 195-198.

Franklin, A., Parmentier-Batteur, S., Walter, L., Greenberg, D. A., and Stella, N. (2003). Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility. J. Neurosci. 23(21), 7767-7775.

Galiegue, S., Mary, S., Marchand, J., Dussossoy, D., Carriere, D., Carayon, P., Bouaboula, M., Shire, D., Le Fur, G., and Casellas, P. (1995). Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 232(1), 54-61.

Gallagher, R., Collins, S., Trujillo, J., McCredie, K., Ahearn, M., Tsai, S., Metzgar, R., Aulakh, G., Ting, R., Ruscetti, F., and Gallo, R. (1979). Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promye-locytic leukemia. Blood 54(3), 713-733.

Garrido, E., Delgado, M., Martinez, C., Gomariz, R. P., and De la Fuente, M. (1996). Pituitary adenylate cyclase-activating polypeptide (PACAP38) modulates lymphocyte and macrophage functions: Stimulation of adherence and opposite effect on mobility. Neuropeptides 30(6), 583-595.

Gillitzer, R., and Goebeler, M. (2001). Chemokines in cutaneous wound healing. J. Leukoc. Biol. 69(4), 513-521.

Gomes, I., Gupta, J. A., Trapaidze, N., Nagy, V., and Devi, L. A. (2000). Heterodimeriza-tion of m and d opioid receptors: A role in opiate synergy. J. Neurosci. 20, RC110.

Grimm, M. C., Ben-Baruch, A., Taub, D. D., Howard, O. M. Z., Resau, J. H., Wang, J. M., Ali, H., Richardson, R., Snyderman, R., and Oppenheim, J. J. (1998). Opiates transdeactivate chemokine receptors: Delta and mu opiate receptor-mediated heterologous desensitization. J. Exp. Med. 188(2), 317-325.

Grimsey, N. L., Goodfellow, C. E., Scotter, E. L., Dowie, M. J., Glass, M., and Graham, E. S. (2008). Specific detection of CB1 receptors: Cannabinoid CB1 receptor antibodies are not all created equal. J. Neurosci. Methods 171, 78-86.

Hanus, L., Gopher, A., Almog, S., and Mechoulam, R. (1993). 2-Arachidonoyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. USA 98, 3032-3034.

Harvath, L., Robbins, J. D., Russell, A. A., and Seamon, K. B. (1991). cAMP and human neutrophil chemotaxis. Elevation of cAMP differentially affects chemotactic responsiveness. J. Immunol. 146(1), 224-232.

Heiner, I., Eisfeld, J., and Luckhoff, A. (2003). Role and regulation of TRP channels in neutrophil granulocytes. Cell Calcium 33, 533.

Henstridge, C., Balenga, N., Campbell, G., Waldhoer, M., and Irving, A. (2008). The GPR55 ligand, L-a-lysophosphatidylinositol, promotes RHO-dependent Ca2+ signaling. 18th Ann. Symp. ICRS, Abstract, p. 14.

Hiley, C. R., and Kaup, S. S. (2007). GPR55 and the vascular receptors for cannabinoids. Br. J. Pharmacol. 152, 559-561.

Ho, W.-S. V., and Hiley, C. R. (2003). Vasodilator actions of abnormal-cannabidiol in rat isolated small mesenteric artery. Br. J. Pharmacol. 138(7), 1320-1332.

Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., Mechoulam, R., and Pertwee, R. G. (2002). International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54(2), 161-202.

Hurley, J. V. (1983). Acute Inflammation, 2nd ed Churchill Livingston, Edinburgh.

Hwang, J.-I., Fraser, I. D. C., Choi, S., Qin, X.-F., and Simon, M. I. (2004). Analysis of C5a-mediated chemotaxis by lentiviral delivery of small interfering RNA. Proc. Natl. Acad. Sci. USA 101(2), 488-493.

Imhof, B. A., and Dunon, D. (1997). Basic mechanism of leukocyte migration. Hormone Metab. Res. 29(12), 614-621.

Jarai, Z., Wagner, J. A., Varga, K., Lake, K. D., Compton, D. R., Martin, B. R., Zimmer, A. M., Bonner, T. I., Buckley, N. E., Mezey, E., Razdan, R. K., Zimmer, A., et al. (1999). Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. USA 96(24), 14136-14141.

Jockusch, B. M., Bubeck, P., Giehl, K., Kroemker, M., Moschner, J., Rothkegel, M., Rudiger, M., Schluter, K., Stanke, G., and Winkler, J. (1995). The molecular architecture of focal adhesions. Ann. Rev. Cell Dev. Biol. 11, 379-416.

Johns, D. G., Behm, D. J., Walker, D. A., Ao, Z., Shapland, E. M., Daniels, D. A., Riddick, M., Dowell, S., Staton, P. C., and Green, P. (2007). The novel endocannabi-noid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br. J. Pharmacol. 152, 825-831.

Joseph, J., Niggemann, B., Zaenker, K. S., andEntschladen, F. (2002). The neurotransmitter gamma-aminobutyric acid is an inhibitory regulator for the migration of SW 480 colon carcinoma cells. Cancer Res. 62(22), 6467-6469.

Joseph, J., Niggemann, B., Zaenker, K. S., andEntschladen, F. (2004). Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes. Cancer Immunol. Immunother. 53(8), 723-728.

Kaminski, N. E., Abood, M. E., Kessler, F. K., Martin, B. R., and Schatz, A. R. (1992). Identification ofa functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation. Mol. Pharmacol. 42(5), 736-742.

Kane, S. (2001). Caring for women with inflammatory bowel disease. JGSM 4(1), 54-59.

Kayali, A. G., Van Gunst, K., Campbell, I. L., Stotland, A., Kritzik, M., Liu, G., Flodstrom-Tullberg, M., Zhang, Y.-Q., and Sarvetnick, N. (2003). The stromal cell-derived factor-1a/CXCR4 ligand-receptor axis is critical for progenitor survival and migration in the pancreas. J. Cell Biol. 163(4), 859-869.

Kishimoto, S., Gokoh, M., Oka, S., Muramatsu, M., Kajiwara, T., Waku, K., and Sugiura, T. (2003). 2-Arachidonoylglycerol induces the migration of HL-60 cells differentiated into macrophage-like cells and human peripheral blood monocytes through the cannabinoid CB2 receptor-dependent mechanism. J. Biol. Chem. 278(27), 24469-24475.

Kishimoto, S., Muramatsu, M., Gokoh, M., Oka, S., Waku, K., and Sugiura, T. (2005). Endogenous cannabinoid receptor ligand induces the migration of human natural killer cells. J. Biochem. 137(2), 217-223.

Kozasa, T., Jiang, X., Hart, M. J., Sternweis, P. M., Singer, W. D., Gilman, A. G., Bollag, G., and Sternweis, P. C. (1998). p115 RhoGEF, a GTPase activating protein for Galpha12 and Galpha13. Science 28o(5372), 2109-2111.

Kucharzik, T., and Williams, I. R. (2003). Neutrophil migration across the intestinal epithelial barrier—Summary of in vitro data and description of a new transgenic mouse model with doxycycline-inducible interleukin-8 expression in intestinal epithelial cells. Pathobiology 70(3), 143-149.

Kunos, G., Jarai, Z., Batkai, S., Goparaju, S. K., Ishac, E. J. N., Liu, J., Wang, L., and Wagner, J. A. (2000). Endocannabinoids as cardiovascular modulators. Chem. Phys. Lipids 108(1-2), 159-168.

Kurihara, R., Tohyama, Y., Matsusaka, S., Naruse, H., Kinoshita, E., Tsujioka, T., Katsumata, Y., and Hirohei, Y. (2006). Effects of peripheral cannabinoid receptor ligands on motility and polarization in neutrophil-like HL60 cells and human neutrophils. J. Bio/.

Chem. 281, 12908-12918.

Kwiatkowski, A. V., Gertler, F. B., and Loureiro, J. J. (2003). Function and regulation of Ena/VASP proteins. Trends Cell Biol. 13(7), 386-392.

Lee, N. H., and El-Fakahany, E. E. (1991). Allosteric antagonists of the muscarinic acetylcholine receptor. Biochem. Pharmacol. 42(2), 199—205.

Levine, J., and Taiwo, Y. (1994). Inflammatory pain. In ''Textbook of Pain'' (P. D. Wall and R. Melzack, Eds.), 3rd ed. Churchill Livingston, London.

Levine, J. D., Lau, W., Kwiat, G., and Goetzl, E. J. (1984). Leukotriene B4 produces hyperalgesia that is dependent on polymorphonuclear leukocytes. Science 225(4663), 743-745.

Levine, J. D., Gooding, J., and Donatoni, P. (1985). The role of the polymorphonuclear leukocyte in hyperalgesia. J. Neurosci. 5(11), 3025-3029.

Levine, J. D., Lam, D., and Taiwo, Y. O. (1986). Hyperalgesic properties of 15-lipoxygenase products of arachidonic acid. Proc. Natl. Acad. Sci. USA 83(14), 5331-5334.

Lodish, H., Berk, A., Baltimore, D., and Darnell, J. (2000). Molecular Cell Biology. W. H. Freeman & Co Ltd., New York.

Lu, Q., Straiker, A., Lu, Q., and Maguire, G. (2000). Expression of CB2 cannabinoid receptor mRNA in adult rat retina. Visual Neurosci. 17(1), 91-95.

Lunn, C. A., Fine, J. S., Rojas-Triana, A., Jackson, J. V., Fan, X. D., Kung, T. T., Gonsiorek, W., Schwarz, M. A., Lavey, B., and Kozlowski, J. A. (2006). A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. J. Pharmacol. Exp. Ther. 316, 780-788.

Luo, B., Prescott, S. M., and Topham, M. K. (2003). Protein kinase Ca phosphorylates and negatively regulates diacylglycerol kinase zeta. J. Biol. Chem. 278(41), 39542-39547.

Luttrel, L. M., Ferguson, S. S. G., Daaka, Y., Miller, W. E., Maudsley, S., Della Rocca, G. J., Lin, F.-T., Kawakatsu, H., Owada, K., Luttrell, D. K., Caron, M. G., and Lefkowitz, R. J. (1999). Beta-arrestin-dependent formation of Beta2 adrenergic receptor-Src protein kinase complexes. Science 283(5402), 655-661.

Mackie, K., and Stella, N. (2006). Cannabinoid receptors and endocannabinoids: Evidence for new players. AAPS J. 8, E298-E306.

Mackie, K., Devane, W. A., and Hille, B. (1993). Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol. Pharmacol. 44(3), 498-503.

MacLennan, S. J., Reynen, P. H., Kwan, J., and Bonhaus, D. W. (1998). Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors. Br. J. Pharmacol. 124(4), 619-622.

Massi, P., Patrini, G., Rubino, T., Fuzio, D., and Parolaro, D. (1997). Changes in rat spleen cannabinoid receptors after chronic CP-55,940: An autoradiographic study. Pharmacol. Biochem. Behav. 58(1), 73-78.

Masur, K., Niggemann, B., Zanker, K. S., and Entschladen, F. (2001). Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers. Cancer Res. 61(7), 2866-2869.

Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., and Bonner, T. I. (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346(6284), 561-564.

McHugh, D., Tanner, C., Mechoulam, R., Pertwee, R. G., and Ross, R. A. (2008). Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocan-nabinoids: Evidence for a site distinct from CB1 and CB2. Mol. Pharmacol. 73(2), 441-450.

Mechoulam, R., Ben-Shabata, S., Hanua, L., Ligumskya, M., Kaminskib, N. E., Schatzd, A. R., Gopherc, A., Almogc, S., Martind, B. R., Comptond, D. R., Pertwee, R. G., Griffine, G., et al. (1995). Identification of an endogenous 2-monoglyc-eride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol.

Miller, A., and Stella, N. (2008). CB2 receptor-mediated migration of immune cells: It can go either way. Br. J. Pharmacol. 153, 299—308.

Milman, G., Maor, Y., Abu-Lafi, S., Horowitz, M., Gallily, R., Batkai, S., Mo, F.-M., Offertaler, L., Pacher, P., and Kunos, G. (2006). N-arachidonoyl-L-serine, an endogenous endocannabinoid-like brain constituent with vasodilatory properties. Proc. Natl. Acad. Sci. USA 103, 2428-2433.

Mitsui, H., Takuwa, N., Kurokawa, K., Exton, J. H., and Takuwa, Y. (1997). Dependence of activated Galpha12-induced G1 to S phase cell cyclin progression on both Ras/ mitogen-activated protein kinase and Ras/Rac1/Jun N-terminal kinase cascades in NIH3T3 fibroblasts. J. Biol. Chem. 272(8), 4904-4910.

Mo, F. M., Offertaler, L., and Kunos, G. (2004). Atypical cannabinoid stimulates endothelial cell migration via a G i/Go-coupled receptor distinct from CB1, CB2 or EDG-1. Eur. J. Pharmacol. 489(1-2), 21-27.

Moser, B., and Ebert, L. (2003). Lymphocyte traffic control by chemokines: Follicular B helper T cells. Immunol. Lett. 85(2), 105-112.

Movat, H. Z. (1985). The Inflammatory Reaction. Elsevier, Amsterdam.

Munro, S., Thomas, K. L., and Abu-Shaar, M. (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365(6441), 61-65.

Narumiya, S. (1996). The small GTPase Rho: Cellular functions and signal transduction. J. Biochem. 120(2), 215-228.

Nathan, C. (2006). Neutrophils and immunity: Challenges and opportunities. Nat. Rev. Immunol. 6, 173-182.

Neer, E. J. (1995). Heterotrimeric G proteins: Organizers of transmembrane signals. Cell 80(2), 249-257.

Neptune, E. R., and Bourne, H. R. (1997). Receptors induce chemotaxis by releasing the betagamma subunit of G(i), not by activating G(q) or G(s). Proc. Natl. Acad. Sci. USA 94(26), 14489-14494.

Nilsson, O., Fowler, C. J., and Jacobsson, S. O. (2006). The cannabinoid agonist WIN 55, 212-2 inhibits TNF-alpha-induced neutrophil transmigration across ECV304 cells. Eur. J. Pharmacol. 547, 165-173.

Offertaler, L., Mo, F.-M., Batkai, S., Liu, J., Begg, M., Razdan, R. K., Martin, B. R., Bukoski, R. D., and Kunos, G. (2003). Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol. Pharmacol. 63(3), 699-705.

Oka, S., Ikeda, S., Kishimoto, S., Gokoh, M., Yanagimoto, S., Waku, K., and Sugiura, T. (2004). 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces the migration of EoL-1 human eosinophilic leukemia cells and human peripheral blood eosinophils. J. Leukoc. Biol. 76(5), 1002-1009.

Oka, S., Nakajima, K., Yamashita, A., Kishimoto, S., and Sugiura, T. (2007). Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem. Biophys. Res. Commun. 362, 928-934.

Okamoto, H., Takuwa, N., Yokomizo, T., Sugimoto, N., Sakurada, S., Shigematsu, H., and Takuwa, Y. (2000). Inhibitory regulation of Rac activation, membrane ruffling, and cell migration by the G protein-coupled sphingosine-1-phosphate receptor EDG5 but not EDG1 or EDG3. Mol. Cell. Biol. 20(24), 9247-9261.

O'Sullivan, S. E., Kendall, D. A., and Randall, M. D. (2006). Characterisation of the vasorelaxant properties of the novel endocannabinoid N-arachidonoyl dopamine (NADA). Br. J. Pharmacol. 141, 803-812.

Pereira, H. A., Shafer, W. M., Pohl, J., Martin, L. E., and Spitznagel, J. K. (1990). CAP37, a human neutrophil-derived chemotactic factor with monocyte specific activity. J. Clin. Invest. 85(5), 1468-1476.

Pertwee, R. G. (1997). Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther. 74(2), 129-180.

Pertwee, R. G. (2001). Cannabinoid receptors and pain. Prog. Neurobiol. 63(5), 569—611.

Pertwee, R. G. (2004). Novel pharmacological targets for cannabinoids. Curr. Neuropharmacol. 2(1), 9-29.

Pertwee, G. R. (2005). The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J. 7(3), E625-E654.

Pertwee, R. G. (2007). GPR55: A new member of the cannabinoid clan? Br. J. Pharmacol. 152, 984-986.

Pertwee, R. G., and Ross, R. A. (2002). Cannabinoid receptors and their ligands. Prostaglandins Leukot. Essent. Fatty Acids 66(2-3), 101-121.

Petitet, F., Jeantaud, B., Reibaud, M., Imperato, A., and Dubroeucq, M. (1998). Complex pharmacology of natural cannabinoids: Evidence for partial agonist activity of Delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci. 63(1), P1-P6.

Pierce, K. L., Premont, R. T., and Lefkowitz, R.J. (2002). Seven-transmembrane receptors. Nat. Rev. Mol. Cell Biol. 3(9), 639-650.

Porter, A. C., Sauer, J.-M., Knierman, M. D., Becker, G. W., Berna, M. J., Bao, J., Nomikos, G. G., Carter, P., Bymaster, F. P., Leese, A. B., and Felder, C. C. (2002). Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J. Pharmacol. Exp. Ther. 301(3), 1020-1024.

Rahaman, M., Costello, R. W., Belmonte, K. E., Gendy, S., and Walsh, M. (2006). Neutrophil sphingosine-1-phosphate and lysophosphatidic acid receptors in pneumonia. AJRCMB 34, 233-241.

Riento, K., and Ridley, A. J. (2003). Rocks: Multifunctional kinases in cell behaviour. Nat. Rev. Mol. Cell Biol. 4(6), 446-456.

Rinaldi-Carmona, M., Barth, F., Millan, J., Derocq, J.-M., Casellas, P., Congy, C., Oustric, D., Sarran, M., Bouaboula, M., Calandra, B., Portier, M., Shire, D., et al. (1998). SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 284(2), 644-650.

Ross, R. A., Brockie, H. C., Stevenson, L. A., Murphy, V. L., Templeton, F., Makriyannis, A., and Pertwee, R. G. (1999). Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630. Br. J. Pharmacol. 126(3), 665-672.

Ross, R. A., Gibson, T. M., Brockie, H. C., Leslie, M., Pashmi, G., Craib, S. J., Di Marzo, V., and Pertwee, R. G. (2001). Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. Br. J. Pharmacol. 132(3), 631-640.

Ryberg, E., Larsson, N., Sjorgen, S., Hjorth, S., Hermansson, N.-O., Leonova, J., Elebring, T., Nilsson, K., Drmota, T., and Greasley, P. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol. 152, 1092-1101.

Sacerdote, P., Massi, P., Panerai, A. E., and Parolaro, D. (2000). In vivo and in vitro treatment with the synthetic cannabinoid CP55,940 decreases the in vitro migration of macrophages in the rat: Involvement of both CB1 and CB2 receptors. J. Neuroimmunol. 109(2), 155-163.

Sagi, S. A., Seasholtz, T. M., Kobiashvili, M., Wilson, B. A., Toksoz, D., and Brown, J. H. (2001). Physical and functional interactions of Gaq with Rho and its exchange factors. J. Biol. Chem. 276(18), 15445-15452.

Sallusto, F., Schaerli, P., Loetscher, P., Schaniel, C., Lenig, D., Mackay, C. R., Qin, S., and Lanzavecchia, A. (1998). Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur. J. Immunol. 28(9), 2760-2769.

Sanchez-Madrid, F., and Del Pozo, M. A. (1999). Leukocyte polarization in cell migration and immune interactions. EMBO J. 18, 501-511.

Sawzdargo, M., Nguyen, T., Lee, D. K., Lynch, K. R., Cheng, R., Heng, H. H. Q., George, S. R., and O'Dowd, B. F. (1999). Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Mol. Brain Res. 64(2), 193—198.

Schuligoi, R. (1998). Effect of colchicine on nerve growth factor—Induced leukocyte accumulation and thermal hyperalgesia in the rat. Naunyn Schmiedebergs Arch. Pharmacol. 358(2), 264-269.

Senior, R. M., Griffin, G. L., and Huang, J. S. (1983). Chemotactic activity of platelet alpha granule proteins for fibroblasts. J. Cell Biol. 96(2), 382-385.

Showalter, V. M., Compton, D. R., Martin, B. R., and Abood, M. E. (1996). Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): Identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther. 278(3), 989-999.

Smart, D., Gunthorpe, M. J., Jerman, J. C., Nasir, S., Gray, J., Muir, A. I., Chambers, J. K., Randall, A. D., and Davis, J. B. (2000). The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br. J. Pharmacol. 129(2), 227-230.

Snyderman, R., and Uhing, R. J. (1992). Chemoattractant stimulus-response coupling. /n ''Inflammation: Basic Principles and Clinical Correlates'' (J. I. Gallin, I. M. Goldstein, and R. Snyderman, Eds.), 2nd ed., pp. 421-439. Raven Press Ltd., New York.

Somlyo, A. P., and Somlyo, A. V. (2003). Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: Modulated by G proteins, kinases, and myosin phosphatase. Physiol. Rev. 83 (4), 1325-1358.

Song, Z.-H., and Zhong, M. (2000). CB1 cannabinoid receptor-mediated cell migration. J. Pharmacol. Exp. Ther. 294(1), 204-209.

Stevens, A., and Lowe, J. S. (1996). Human Histology, 2nd ed. Mosby, London.

Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., and Waku, K. (1995). 2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215(1), 89-97.

Sugiura, T., Kondo, S., Kishimoto, S., Miyashita, T., Nakane, S., Kodaka, T., Suhara, Y., Takayama, H., and Waku, K. (2000). Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J. Biol. Chem. 275(1), 605-612.

Territo, M. C., Ganz, T., Selsted, M. E., and Lehrer, R. (1989). Monocyte-chemotactic activity of defensins from human neutrophils. J. Clin. Invest. 84(6), 2017-2020.

Thiele, J., Varus, E., Wickenhauser, C., Kvasnicka, H. M., Metz, K. A., and Beelen, D. W. (2004). Regeneration of heart muscle tissue: Quantification of chimeric cardiomyocytes and endothelial cells following transplantation. Histol. Histopathol. 19(1), 201-209.

Vaccani, A., Massi, P., Colombo, A., Rubino, T., and Parolaro, D. (2005). Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. Br. J. Pharmacol. 144(8), 1032-1036.

Van Haastert, P. J. M., and Devreotes, P. N. (2004). Chemotaxis: Signalling the way forward. Nat. Rev. Mol. Cell Biol. 5, 626-634.

Wagner, J. A., Varga, K., Jarai, Z., and Kunos, G. (1999). Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension 33(Part II), 429-434.

Walker, J. M., Krey, J. F., Chu, C. J., and Huang, S. M. (2002). Endocannabinoids and related fatty acid derivatives in pain modulation. Chem. Phys. Lipids 121(1-2), 159-172.

Walter, L., Franklin, A., Witting, A., Wade, C., Xie, Y., Kunos, G., Mackie, K., and Stella, N. (2003). Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J. Neurosci. 23(4), 1398-1405.

Ward, P. A. (1997). Neutrophils and adjuvant arthritis. Clin. Exp. Immunol. 107(2), 225-226.

Wenzel-Seifert, K., Hurt, C. M., and Seifert, R. (1998). High constitutive activity of the human formyl peptide receptor. J. Biol. Chem. 273(37), 24181-24189.

Whyte, L., Ryberg, E., Ridge, S., Mackie, K., Greasley, P., Rogers, M. J., and Ross, R. (2008). GPR55 is involved in the regulation of Osteoclast activity in vitro and bone mass in vivo 18th Ann. Symp. ICRS, Abstract p. 50.

Wiley, J. L., and Martin, B. R. (2002). Cannabinoid pharmacology: Implications for additional cannabinoid receptor subtypes. Chem. Phys. Lipids 121(1-2), 57-63.

Wright, C. D., Kuipers, P. J., Kobylarz-Singer, D., Devall, L. J., Klinkefus, B. A., and Weishaar, R. E. (1990). Differential inhibition of human neutrophil functions: Role of cyclic AMP-specific, cyclic GMP-insensitive phosphodiesterases. Biochem. Pharmacol. 40(4), 699-707.

Wysocka, J., Turowski, D., Lipska, A., and Milkolajczyk-Kwapisz, M. (1997). Participation of neutrophils in pathophysiology of unstable angina pectoris. Pol. Merkur. Lekarski.

Xu, J., Wang, F., Van Keymeulen, A., Herzmark, P., Straight, A., Kelly, K., Takuwa, Y., Sugimoto, N., Mitchison, T., and Bourne, H. R. (2003). Divergent signals and cyto-skeletal assemblies regulate self-organizing polarity in neutrophils. Cell 114, 201-214.

Yokomizo, T., Masuda, K., Kato, K., Toda, A., Izumi, T., and Shimizu, T. (2000). Leukotriene B4 receptor: Cloning and intracellular signaling. Am. J. Respir. Crit. Care Med. 161(2 II), S51-S55.

Zhang, X. F., Wang, J. F., Maor, Y., Kunos, G., and Groopman, J. E. (2005). Endogenous cannabinoid-like arachidonoyl serine induces angiogensis through novel pathways (Abstract). Blood 106, 3690.

Ziegler, W. H., Tigges, U., Zieseniss, A., and Jockusch, B. M. (2002). A lipid-regulated docking site on vinculin for protein kinase C. J. Biol. Chem. 277(9), 7396-7404.

Zygmunt, P. M., Petersson, J., Andersson, D. A., Chuang, H., Sorgard, M., Di Marzo, V., Julius, D., and Hogestatt, E. D. (1999). Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400(6743), 452-457.

Zygmunt, P. M., Andersson, D. A., and Hogestatt, E. D. (2002). Delta -tetrahydrocannabinol and cannabinol activate capsaicin-sensitive sensory nerves via a CB1 and CB2 cannabinoid receptor-independent mechanism. J. Neurosci. 22(11), 4720-4727.

Was this article helpful?

0 0

Post a comment